

8 : 30–9 : 30

Room 10 (G510, Tokyo International Forum)

O64 English Session 4

Driver Mutant Lung Cancer 2

Chairs : Tetsu Kobayashi
Mie University
Joseph A. Treat
Fox Chase Cancer Center, USA

1. Tepotinib in patients (pts) with *MET* ex14 skipping NSCLC from VISION study : ≥ 3 -year follow-up
Tomohiro Sakamoto
Department of Respiratory Medicine, Tottori University Hospital, Japan
2. The combined impact of EGFR L858R and TP53 co-mutations on survival with first-line osimertinib
Joseph A. Treat
Fox Chase Cancer Center, USA
3. Alectinib vs crizotinib in *ALK*+ NSCLC : PFS in patients without/with prior chemotherapy in J-ALEX
Nobuyuki Yamamoto
Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan
4. A Case of NSCLC with Rare *ALK* Fusion (NAPB/IR/CCSER1) : Clinical Course and Response to Iru-plinalkib
Yalei Zhang
Department of Thoracic Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5. Real-world characterization of HER2-altered NSCLC patients who received second-line therapy in Japan
Yuji Uehara
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
6. Repotrectinib in *ROS1*+NSCLC : Long-Term Follow-Up from Phase 1/2 TRIDENT-1 Trial
Koichi Goto
National Cancer Center Hospital East, Japan

9 : 35–10 : 35

Room 10 (G510, Tokyo International Forum)

O65 English Session 5

Trials in Progress and Translational Research

Chairs : Shinichi Sasaki
Juntendo University Graduate School of Medicine
Solange Peters
Lausanne University Hospital (CHUV), Switzerland

1. Improved Survival and DCR with HITOC and Targeted Therapy in Advanced Lung Adenocarcinoma with MPE
Zhilin Luo
Department of Thoracic Surgery, the Third Affiliated Hospital of Chongqing Medical University, China
2. Non-invasive image-quantitation of anticancer aerosol delivery using Magnetic Particle Imaging
Zhiwei Tay
Health and Medical Research Institute, National Inst. of Advanced Industrial Science and Technology, Japan
3. Metabolic Solid Score : Integrating Metabolic Activity and Radiologically Solid Size in Lung Cancer
Haoji Yan
Department of General Thoracic Surgery, Juntendo University, Tokyo, Japan

4. Enhancing Enrollment to IL NSCLC Trials By Allowing 1 Prior Cycle of Standard of Care : SUNRAY-01

Makoto Nishio

Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan

5. A Phase II Trial of LP-300 plus Carboplatin and Pemetrexed in TKI-Progressed NSCLC Patients

Jonathan Dowell

Department of Internal Medicine, UT Southwestern Medical Center, United States of America

6. A phase I study of LY4050784, a SMARCA2 inhibitor, in advanced solid tumors with SMARCA4 alterations

Tatsuya Yoshida

National Cancer Center Hospital, Tokyo, Japan

10 : 05–10 : 55

Room 1 (Hall C, Tokyo International Forum)

Invited Lecture 7

Chair : Kenji Suzuki

Juntendo University Graduate School of Medicine

Innovations in the Oncologic Surgery for Thymic Malignancies

Chang Hyun Kang

Seoul National University College of Medicine/Seoul National University Hospital, Korea

10 : 40–11 : 40

Room 10 (G510, Tokyo International Forum)

O66 English Session 6

IO and Driver Mutant Lung Cancer

Chairs : Takaaki Sasaki

Asahikawa Medical University

Geoffrey Liu

Princess Margaret Cancer Centre, Canada

1. LIGHT-NING final analysis : 1L nivolumab+ipilimumab +/- chemotherapy for NSCLC in Japan

Teppei Yamaguchi

Department of Thoracic Oncology, Aichi Cancer Center Hospital

2. 1st line (1L) nivolumab+ipilimumab+chemo (N+I+C) in metastatic (m) NSCLC : CheckMate 9LA 6y data

Satoshi Ikeda

Kanagawa Cardiovascular and Respiratory Center / Kansai Medical University

3. Final Safety Analysis of First-Line Nivolumab+Ipilimumab +/- Chemotherapy for NSCLC in Japan

Kazuma Kishi

Department of Respiratory Medicine, Toho University Omori Medical Center

4. Subsequent Therapy in Metastatic NSCLC Treated with Nivolumab+Ipilimumab +/- Chemotherapy

Koichi Azuma

Division of Respiriology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University, School of Medicine

5. Resectable NSCLC Following Neoadjuvant Immunotherapy : Should Adjuvant Immunotherapy Be Recommended?

MING LI

Zhongshan Hospital, Fudan University, China

6. Real-world 1L treatment for advanced NSCLC patients with PD-L1 $\geq$ 50% and without AGA in EU, US and APAC

Hirotsugu Kenmotsu

Shizuoka Cancer Center, Shizuoka, Japan

11 : 00–11 : 40

Room 6 (Hall D7, Tokyo International Forum)

Invited Lecture 9

Chair : Kazuhiro Suzuki
Faculty of Medicine, Juntendo University

AI and fMRI for Patients with Lung Cancer and Brain Lesions

Haris Sair
The Johns Hopkins University School of Medicine, USA

12 : 00–12 : 50

Room 2 (Hall B7 (1), Tokyo International Forum)

Luncheon Seminar 23

The Optimal Solution Varies by Country : What pharmacological therapies are best suited for EGFR mutation-positive lung cancer in the Japanese population?

Chair : Takashi Seto
Kyushu Cancer Center

1. EGFR-Positive Lung Cancer Therapy : Perspectives from U.S. Physicians

Joseph A. Treat
Fox Chase Cancer Center, USA

2. Optimizing Treatment Strategies for Long-Term Overall Survival in Japan

Kazuhiko Nakagawa
Kindai University Hospital Cancer Center

Eli Lilly Japan K.K.

12 : 00–12 : 50

Room 3 (Hall B7 (2), Tokyo International Forum)

Luncheon Seminar 24

Chair : Toshiaki Takahashi
Shizuoka Cancer Center

Perioperative immunotherapy for resectable NSCLC. Expectations from the AEGEAN regimen and other combinations.

Solange Peters
Lausanne University Hospital (CHUV), Switzerland

Astrazeneca K.K.

12 : 00–12 : 50

Room 4 (Hall B5 (1), Tokyo International Forum)

Luncheon Seminar 25

Chair : Yasushi Goto
National Cancer Center Hospital

DLL3 Targeted Therapy in 3L SCLC : Translating Clinical Evidence into Practice.

Jacob Sands
Dana-Farber Cancer Institute, USA

Amgen K.K.

12 : 00–12 : 50

Room 10 (G510, Tokyo International Forum)

Luncheon Seminar 31

Chair : Naoya Murakami
Juntendo University Graduate School of Medicine

Staging of Lung Cancer : Focused on Imaging

Jin Mo Goo
Seoul National University, Department of Radiology, Korea

CANON MEDICAL SYSTEMS CORPORATION

13 : 00–13 : 50

Room 1 (Hall C, Tokyo International Forum)

Invited Lecture 8

Chair : Takehito Shukuya
Juntendo University Graduate School of Medicine

Hope and progress in lung cancer

David P. Carbone
The Ohio State University, USA